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ABSTRACT
Human leukocyte antigen (HLA)-B27-associated anterior uveitis (AU) is themost commonly diagnosed formofAUand
represents the largest entity of non-infectious uveitis around theworld. Themost typical ocularmanifestation associated
with HLA-B27 consists of unilateral AU of acute onset. The HLA-B27-associated acute AU represents a distinct clinical
entity occurring typically in young adults between the ages of 20 and 40 years. HLA-B27-associated acute AU is
typically unilateral and lasts usually several weeks and diminishes within 3 months in the majority of patients. The
anterior chamber shows typically severe cellular reaction and flare, as well as a fibrinous exudate. Frequently, posterior
synechiae are formed and occasionally hypopyon is present. The pattern of the disease is recurrent with a full remission
between the attacks. Intraocular pressure during active periods is typically low due to inflammation of ciliary body and
decreased aqueous production. Less typical presentations are also recognized and include the development of chronic
inflammation, posterior segment involvement, episcleritis, and scleritis. An isolated retinal vasculitis in HLA-B27-
positive patients may develop, mostly in those with inflammatory bowel disease. Chronic AU, which may be either
unilateral or bilateral affects up to 20% of patients. Ocular complications of HLA-B27-associated AU are diverse and
include commonly posterior synechiae, cataract, glaucoma and/or hypotony. The visual outcome and complications of
HLA-B27-associated AAU are frequently being compared with HLA B27-negative patients with AU and show that the
prognosis of HLA-B27-associated uveitis is rather favorable, as <2% developed legal blindness and <5% visual
impairment. A novel algorithm called the “Dublin Uveitis Evaluation Tool (DUET)” has been proposed to guide
ophthalmologists to refer appropriate HLA-B27-positive patients with uveitis to rheumatologists.
Keywords: HLA B27-associated uveitis, clinical manifestations, anterior uveitis, acute anterior uveitis
Uveitis represents an important ocular manifestation
in patients with human leucocyte antigen (HLA)-B27-
associated systemic disorders such as ankylosing spon-
dylitis (AS), reactive arthritis, inflammatory bowel dis-
ease (IBD), and psoriatic arthritis, but HLA-B27-
associated uveitis regularly manifests as an isolated
ocular disorder without other systems being involved.
HLA-B27-associated acute anterior uveitis (AAU)
represents the most frequent ocular disorder asso-
ciated with HLA-B27.
Anterior uveitis (AU) is the most common form of
uveitis encountered by ophthalmologists in the majority
of populations.1–3 AU reaches prevalence of 80% in the
total uveitis population in general ophthalmological prac-
tice, but the prevalence of AU from tertiary centers, which
are a subject to referral bias towards posterior and
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panuveitis, tends to be much lower (~25%).1–3 The preva-
lence of HLA-B27 varies among different population
groups. In most Caucasian populations, the prevalence
of HLA-B27 is approximately 8%, while in African, Arab,
and Asian populations, the prevalence is lower (~1–5%),
which also reflects the lower prevalence ofHLA-B27-asso-
ciated AU in these regions (0.3–14% vs 13–32% in
Caucasian populations).4–6
EPIDEMIOLOGY AND FREQUENCY OF
HLA-B27-ASSOCIATED UVEITIS
The frequencies of HLA-B27-associated AU in large
surveys of uveitis are illustrated in Table 1, in which
the studies from the last decade are summarized.2,6–29
The HLA-B27-associated AU was diagnosed in
approximately 2–14% in large surveys, which included
all patients with uveitis. This variation can be
explained by the variable percentage of patients with
anterior uveitis in a given series and moreover,
depends on HLA-B27 frequency in a specific popula-
tion and probably on yet unidentified environmental
factors. Studies which include AU or AAU patients
solely, usually indicate a higher frequency of HLA-
B27-associated uveitis of approximately 33–67% across
different racial groups, except in one study from Saudi
Arabia, in which HLA-B27-associated uveitis was only
0.6% (Table 2) .5,30–37 In addition to genuine differ-
ences, these distinctions might be a consequence of
TABLE 1. Human leukocyte antigen (HLA)-B27-associated uveitis in uveitis surveys from the last decade.
First author, year Countrya Patients (n) AU (%) IU (%) Post-U (%) Pan-U (%)
HLA-B27-associated AU in all
With uveitis (%) With AU (%)
Grajewski et al. (2015)7 Germany 474 53 19 21 7 10 19
Llorenç et al. (2015)8 Spain 1022 52 9 23 15 13 24
Abdulaal et al. (2014)9 Lebanon 209 26 12 25 38 2.8 7.5
Rahimi et al. (2014)10 Iran 475 40 11 28 21 2 5
Al-Shakarchi (2014)11 Iraq 318 24 6 40 30 – –
Al Dhahri et al. (2014)12 Saudi Arabia 642 37 5 11 47 4.8 7
Liberman et al. (2014)13 Chile 611 40 8 18 33 4 10
Nakahara et al. (2014)14 Japan 468 41 1 17 41 3 7
Silpa-Archa et al. (2014)15 Thailand 446 45 1 14 40 2 4.5
Sittivarakul et al. (2013)16 Thailand 254 35 10 20 35 8 22
Nizamuddin et al. (2013)17 Saudi Arabia 587 57 8 9 26 0.3 5
Barisani-Asenbauer et al. (2012)18 Austria 2619 60 15 18 7 10 17
Cimino et al.19 (2010) Italy 1064 51 6 23 20 5 –
Jakob et al. (2009)2 Germany 1598 52 26 16 7 7 15
De-la-Torre et al. (2009)20 Colombia 693 29 4 36 31 – –
Kitamei et al. (2009)6 Japan 1240 45 - 5 50 4 9
Keino et al. (2009)21 Japan 834 27 1 22 50 2 7
Das et al. (2009)22 India 308 47 13 30 10 11 23
Hamade et al. (2009)23 Saudi Arabia 488 60 6 11 24 2 17
Kazokoglu et al. (2008)24 Turkey 761 53 7 13 28 2.4 7
Pathanapitoon et al. (2008)25 Thailand 200 25 9 46 21 6 24
Rathinam et al. (2007)26 South India 8759 57 10 11 22 – –
Khairallah et al (2007)27 North Africa 472 35 16 28 21 4.4 13
Sengun et al. (2005)28 Turkey 300 44 9 27 21 2 3
Yang et al. (2005)29 China 1752 46 6 7 42 14 31
aAll tertiary centers except in the study of Rathinam SR, et al.,26 which was community-based.
AU, anterior uveitis; IU, intermediate uveitis; Post-U, posterior uveitis; Pan-U, panuveitis.
TABLE 2. Human leukocyte antigen (HLA)-B27-associated uveitis among patients with acute anterior uveitis.
First author, year Country Patients with AU (n)
Positivity of HLA-B27 in patients
with AAU (%)
Associated HLA-B27 systemic
diseases (%)
Karaconji et al. (2013)30 Australia 241 39 11
Torres et al. (2013)31 Cuba 83 55 59
Bawazeer et al. (2013)5 Saudi Arabia 335 0.6 Not determined
Mathur et al. (2012)32 India 42 33 14
Mishra et al. (2011)33 India 89 56 4.5
Park et al. (2009)34 Korea 82 67 53
Accorinti et al. (2010)35 Italy 165 36 50
Pathanapitoon et al. (2006)36 Thailand 121 44 15
Tuncer et al. (2005)37 Turkey 109 40 Not determined
AAU, acute anterior uveitis.
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variable referral to tertiary centers and might be also
influenced by an inconsistent work-up for uveitis,
including the testing for HLA-B27. Similarly, the fre-
quency of systemic disease associated with HLA-B27-
associated uveitis seems to be lower in Japan (1.3%),
India (15%), and Thailand (15%) when compared with
Western countries (~50%).14,32,35,36,38 The association of
AS with HLA-B27 is about 90%. The male preponder-
ance in HLA-B27-associated AU is usually emphasized
(up to 3 times more frequently than in females),
though some studies showed no difference between
the genders.30,34,35,39 Males suffer commonly from
AS, while females had later onset of systemic disease
characterized by undifferentiated spondyloarthropa-
thy and peripheral arthritis.40–42
Types of Ocular Inflammation Associated with
HLA-B27
The most typical ocular manifestation associated with
HLA-B27 consists of unilateral AU of acute onset. The
HLA-B27-associated AAU represents a distinct clinical
entity occurring typically in young adults between the
ages of 20 and 40, and has a frequent association with
seronegative arthritic syndromes, of which the most
prevalent is AS.43 Less common forms of ocular invol-
vement include chronic AU, which is more common in
females, and non-AS systemic disorders, such as IBD
and psoriatic arthritis. Involvement of the posterior
segment (including complications of AU or genuine
posterior uveitis) was also observed as well as
scleritis.44 The activity of uveitis is not necessarily
correlated with the activity of systemic HLA-B27-asso-
ciated disease.45
The HLA-B27-associated AAU is typically unilat-
eral and the intraocular inflammation usually lasts
several weeks and diminishes within 3 months in
the majority of patients. Occasionally, in severe
cases, the time to remission may take longer than
the 3 months, which is usually considered as a divi-
sion border between acute and chronic forms of uvei-
tis. The pattern of the disease is recurrent and HLA-
B27-associated AAU is characterized by a full remis-
sion between the attacks.46 The course of HLA-B27-
associated AAU has a tendency to occur in the first
affected eye, may alternate between the eyes, but both
eyes are almost never affected at the same time.47 The
first episode of HLA-B27-associated AAU commonly
occurs in young adult patients and the frequency of
attacks decreases with the age of the patients. The
cause of the AAU recurrences is not entirely known;
the possible provoking triggers include infections
with Gram-negative bacteria, stress, specific season,
and trauma.48
Intraocular pressure (IOP) during active periods is
typically low due to inflammation of ciliary body
and decreased aqueous production. Sometimes, IOP
may be high due to trabeculitis, accumulation of
inflammatory cells, and debris in the trabecular
meshwork, or the high IOP steroid response.
In hypotonic eyes, the circulation of the cells in the
anterior chamber diminishes and the trabecular
meshwork might easily become damaged, which
leads to persistent high IOP even after the inflamma-
tion subsides. The lower capacity of outflow in
patients with iridocyclitis might result in a situation
when IOP is low during the attacks (due to
decreased aqueous production) and becomes ele-
vated after the inflammation becomes quiet and the
aqueous production is restored. In such cases, the
quick change from high to low IOP is typical.
Posterior segment involvement during AAU is rela-
tively rare, but cystoid macular edema (CME) and
disc edema may develop.
Less Common Forms of HLA-B27-associated
Uveitis
While acute or recurrent, unilateral AU is the most
typical presentation for HLA-B27-associated ocular
inflammation, less typical presentations are also recog-
nized, and include the development of posterior seg-
ment inflammation; chronic or persistent anterior
uveitis; as well as episcleritis and scleritis. Of these
less typical presentations, posterior segment involve-
ment in a patient with HLA-B27-associated uveitis is
perhaps most common, and can include vitritis with or
without pars plana exudates, optic disc swelling or
papillitis, and CME.46,49–51 Hypotony maculopathy
has also been reported in association with severe
HLA-B27-associated AU, but is rare.52,53 It is important
to separate genuine inflammatory involvement located
in the posterior segment from what can be considered
complication of AU, such as CME. Such posterior seg-
ment complications occur most often in the setting of
moderate to severe AU and, as such, are perhaps more
appropriately considered spillover or secondary com-
plications of co-existing anterior segment
inflammation.54 A noteworthy exception appears to
be the occurrence of isolated retinal vasculitis in a
patient with IBD, most often due to Crohn’s disease.-
55–57 Chronic AU, which may be either unilateral or
bilateral, is also well recognized in HLA-B27-positive
patients, affecting up to 20% of patients in some clinic-
based cohorts.39,58–60 By definition, patients with
chronic HLA-B27-associated uveitis require longer-
term treatment, often including systemic immunosup-
pression. Both bilateral involvement and a chronic
disease course appear to be more common in women
and children. HLA-B27-associated episcleritis and
scleritis are uncommon, but can occur.61–63 HLA-B27-
associated posterior scleritis, while reported, appears
to be uncommon.44
© 2017 Taylor & Francis Group, LLC
HLA-B27-associated Ocular Inflammation 571
Complaints and Ocular Clinical Examination
HLA-B27-associated uveitis is generally a benign non-
granulomatous unilateral disease presenting with a
sudden onset of a classic triad of pain, redness, and
photophobia. A 1- or 2-day stage of ocular discomfort
may precede the typical manifestations. Blurred vision
can also be present due to intense exudation into the
anterior chamber and anterior vitreous. This decrease
in visual acuity is greater than in those patients who
are HLA-B27-negative.46 During AAU, patients typi-
cally complain of pain and photophobia; ocular pain
during near distance activities, as reading is also typi-
cal and points out to the presence of cyclitis. Patients
with recurrences commonly recognize this pattern and
consult their ophthalmologist at an early stage, some-
times even before cells in anterior chamber become
detectable. On the other hand, if a patient during an
active attack of HLA-B27-associated AAU reports less
pain and photophobia, usually this indicates that
activity of uveitis is decreasing. This pattern of sub-
jective complaints preceding the objective signs might
be useful when adjusting the treatment.
The main external signs are conjunctival and limbal
hyperemia. Corneal edema may develop due to a
combination of endothelial decompensation and low
intraocular pressure. Anterior segment involvement
may include fine whitish-gray keratic precipitates
and fibrin on the endothelium. Typically, there are no
mutton-fat keratic precipitates.64 The anterior chamber
shows cells and flare, due to the breakdown of the
blood-aqueous barrier, and in severe inflammation, a
fibrinous exudate in the anterior chamber may occlude
the pupil, ending up with an iris bombé.
Fibrinous membrane formation in the absence of
granulomatous keratic precipitates is a classic presen-
tation of HLA-B27-positive anterior uveitis.64 Sanghvi
et al. reported four patients that could not be distin-
guished from endogenous endophthalmitis. These
patients occupied a position at the margin of the spec-
trum of severity; their symptoms were hyperacute,
with very severe fibrinous uveitis, including vitritis,
which gave rise to suspicion of infectious
endophthalmitis.65 Most patients present with an
intense cellular reaction, 3+ cells in >60% of them.
Iris vessels may be dilated and rarely, spontaneous
hyphema can occur. Due to severe inflammation, pos-
terior synechiae can occur in about 13% of the patients
in the acute phase of the disease.58,59 Typically, the
intraocular pressure in the affected eye is lower than
in the contralateral eye as a result of diminished aqu-
eous humor production by the inflamed ciliary body.
More severe cases with hypotony defined as intraocu-
lar pressure <6 mmHg have been reported. van der
Veer et al. reported five patients who developed severe
anterior uveitis with nearly identical symptoms, and
were specifically associated with hypotony and a ser-
ous retinal detachment.53 The incidence of hypopyon
among HLA-B27-positive patients with AAU was
14.5% compared with 2.2% in HLA-B27-negative
patients. In those patients with more severe presenta-
tions and posterior segment involvement, the inci-
dence of hypopyon was 25% compared with 4.4% of
patients without posterior segment involvement.66
Cells are commonly found in the anterior vitreous
and more rarely, patients can develop diffuse vitritis.50
Additional Examinations
Referral to Rheumatologist or Other Specialist
An HLA-B27 test should be performed on all patients
with recurrent non-granulomatous AU because both the
natural history and the outcomes will be different from
HLA B27-negative patients. On the other hand, seronega-
tive spondyloarthropathies are strongly associated with
both AU and HLA-B27 positivity.67 HLA-B27-positive
AAU may have posterior segment complications that
may need additional testing. CME, papillitis, and retinal
vasculitis have been reported as posterior segment man-
ifestations. Braakenburg et al. reported nine HLA-B27-
positive patients with uveitis and retinal vasculitis.
Ocular coherence tomography (OCT) and fluorescein
angiography may be indicated to detect these
complications.49,50,58,68
Patients with HLA-B27-associated AU are highly
likely to develop several (presumably autoimmune)
diseases known as “seronegative spondyloarthropa-
thies” since their rheumatoid factor is negative. The
likelihood of HLA-B27-positive patients with uveitis to
develop a rheumatic disease varies from 33% to 90%
according to several studies.43 Although the rheuma-
tologic symptoms preceded the first attack of uveitis in
>80% of the cases, there are still a number of patients
in whom uveitis is going to be the first sign. The
ophthalmologist may be the first physician to suspect
spondylitis or sacroiliitis. The prevalence of a rheu-
matic disease increases with the duration of the dis-
ease, and since rheumatologic symptoms may be
overlooked as nonspecific, the ophthalmologists may
play a central role in diagnosing ankylosing
spondylitis.69 The novel evidence-based algorithm
called the “Dublin Uveitis Evaluation Tool (DUET)”
has been proposed to guide ophthalmologists and pri-
mary care physicians to refer appropriate AAU
patients to rheumatologists.70
Visual Outcomes and Complications
Ocular complications in HLA-B27-associated AU are
diverse, and include commonly posterior synechiae,
cataract, ocular hypertension, or glaucoma and hypot-
ony (Table 3) .25,30,31,34,35,39,60 Epiretinal membrane and
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band keratopathy can occur, but are less frequent. The
incidence rate of any ocular complication was 0.22/
eye-year, which is lower than in other uveitis entities,
such as juvenile idiopathic arthritis-associated uveitis
or uveitis associated with Behcet disease.60 The most
common complications consisted of elevated IOP, fol-
lowed by the development of cataract and synechiae,
but the incidence of secondary glaucoma is not known.
Chronic inflammation occurred in approximately 20%
of patients and was associated with a higher rate of
ocular complications.60 CME occurred in 10–30% of
HLA-B27-associated AU and prolonged subclinical
macular edema was documented by OCT, even
despite full clinical and functional recovery.71,72
The visual outcome and complications of HLA-
B27-associated AAU are frequently being compared
with HLA-B27-negative patients with AU or AAU
and therefore, the results of such studies slightly
vary according to the etiology of HLA-B27-negative
counterparts. The comparisons of HLA-B27-positive
and -negative AU outcomes are obviously related to
the causes of HLA-B27-negative AU in a given
population, which might be very different in differ-
ent areas of the world. Moreover, the comparison
with only idiopathic cases depends also on their
previous work-up (e.g., exclusion of viral causes
based on clinical findings solely, or substantiated
by intraocular fluid assessment).
The visual prognosis of HLA-B27-associated
uveitis is rather favorable as <2% developed legal
blindness and <5% visual impairment. Despite the
potential for moderate-to-severe vision loss in up to
10% of patients with HLA-B27-associated uveitis,
individual episodes of anterior uveitis tend to
resolve within 4–6 weeks when adequately treated,
and the overall prognosis is generally good.58,73,74
Loh and Acharya estimated the risk of complica-
tions and vision loss to be ≤20/50 at some stage
during the course of disease, and to be 10-fold
greater in patients with moderate-to-severe inflam-
mation and nearly three times greater in patients
with chronic HLA-B27-associated uveitis. They
added, however, that vision improved to ≥20/40
with treatment in nearly 75% of these patients.60
The risk factors for developing visual loss included
the presence of posterior synechiae at presentation,
corticosteroid-sparing therapy, corticosteroid perio-
cular injections, poorly-controlled inflammation,
chronic development, and male gender.60
Intraocular surgery in patients with HLA-B27-asso-
ciated uveitis has to be taken seriously and a pre-
ventive treatment around the surgery with systemic
and local steroids should be given even in a quiet
eye with previous HLA-B27-associated uveitis.75–78
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